2346 related articles for article (PubMed ID: 15365714)
1. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
5. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
Garcia-Zozaya I
J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
[TBL] [Abstract][Full Text] [Related]
6. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
7. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
8. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
13. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
15. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
16. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
17. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
20. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Olsen J; Gundgaard J; Borris LC
Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
